ARCA Recycling, a Subsidiary of JanOne Inc., Opens Recycling Center in Michigan to Support New Multi-Year Contracts Totaling Millions in Revenue

October 12, 2021

Minneapolis – October 12, 2021 – ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), recently opened a new recycling facility in Grand Rapids, Michigan to support its growth in the state. ARCA was recently awarded multiple contracts to provide appliance recycling services for major Michigan electric utilities through the end of... READ MORE

JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101

September 28, 2021

JanOne’s management is encouraged regarding Recent Discussions on Potential Phase 2b Trial Endpoints and Possible Regulatory Routes for JAN101 as Treatment for Peripheral Artery Disease (PAD) LAS VEGAS, [DATE], 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of treatments for conditions that cause severe pain – in conjunction with... READ MORE

JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients

July 22, 2021

CPC to Manage Planning, Organization, and Day-to-Day Execution of the Trial LAS VEGAS, July 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research (CPC), a full-service academic research organization... READ MORE

JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites

June 23, 2021

Company Fully Prepared to Commence Phase 2b Trials of JAN101 for Peripheral Artery Disease (PAD) as Soon as New Protocol is Approved by the FDA LAS VEGAS, June 23, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today... READ MORE

JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing

June 22, 2021

Global Contract Research Organization (CRO) Avania to Manage All Regulatory Affairs in Connection with JanOne's Phase 2b Trial Preparedness and Execution LAS VEGAS, June 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced its selection of... READ MORE

JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board

June 15, 2021

World leader in addiction science joins team of experts in diseases and disorders that cause chronic pain LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D.... READ MORE

JanOne Engages DC Consulting LLC for Government and Private Sector Initiatives

June 10, 2021

LAS VEGAS, June 10, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has engaged the services of DC Consulting LLC, a strategy and management consulting firm specializing in government affairs, regulatory guidance, marketing strategy,... READ MORE

JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million

February 25, 2021

Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD) LAS VEGAS, Feb. 25, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that is has... READ MORE

JanOne Announces Closing of $6.0 Million Common Stock Offering

February 2, 2021

Net proceeds will help support planning of clinical trials for JAN101, the company’s lead drug candidate LAS VEGAS, February XX, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the closing of previously announced its securities offering... READ MORE